Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04970056 · ClinicalTrials.gov registry record
Pancreatic Cancer Early Detection Consortium
A clinical trial of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer, sponsored by Arbor Research Collaborative for Health.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 20
- Study locations
NCT04970056: Recruiting study of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer, sponsored by Arbor Research Collaborative for Health.
NCT04970056 is a study of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer that is actively recruiting participants, run by Arbor Research Collaborative for Health. The registered enrollment target is 20,000 participants, above the 363-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (5410% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04970056, a study of Pancreatic Ductal Adenocarcinoma and Pancreas Cancer, is actively recruiting participants, sponsored by Arbor Research Collaborative for Health.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Primary Outcome
Diagnosis of PDAC
Conditions Studied
Study Locations (20)
California
- Providence Health and Services - Burbank
- City of Hope - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- UCLA Health - Los Angeles
- Hoag - Newport Beach
- UC Irvine Health - Orange
- UC Davis - Sacramento
- University of California, San Francisco (UCSF) - San Francisco
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
Illinois
- Illinois CancerCare - Bloomington
- University of Chicago Medicine - Chicago
- NorthShore University HealthSystem - Evanston
Arizona
- Mayo Clinic Arizona - Phoenix
- Honor Health Research Institute - Scottsdale
Connecticut
- Yale University - New Haven
Georgia
- Emory University Hospital - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2020-09-18 |
| Est. Completion | 2030-12-31 |
What NCT04970056 shows while recruiting
NCT04970056 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 363-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (5410% higher).
The record links to 4 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04970056 names 20 study sites across 7 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04970056 about?
NCT04970056 is a clinical study titled "Pancreatic Cancer Early Detection Consortium". The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying ...
What is the current status of trial NCT04970056?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2020-09-18. Estimated completion is 2030-12-31.
What conditions does trial NCT04970056 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Genetic Predisposition, Pancreas Cyst.
Who is sponsoring clinical trial NCT04970056?
This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04970056 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04970056's enrollment target sits among peer trials
20,000 1st of 84 higher than 84 of 84 other Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI